Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a gel cut down on skin cancer surgeries? new trial investigates

NCT ID NCT04155190

Disease control Sponsor: Sol-Gel Technologies, Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial tests a gel called patidegib applied to the face twice daily for 9 months in people who develop many basal cell carcinomas (a common skin cancer) but do not have Gorlin syndrome. The goal is to see if the gel reduces the number of new skin cancers that would normally require surgery. Half of the 50 participants receive the active gel, and half receive a placebo gel with no active ingredient.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
patidegib topical gel, 2%
What this could lead to
If effective, patidegib gel could offer a non-surgical way to reduce the number of new basal cell carcinomas on the face, potentially decreasing the need for repeated surgeries.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not confirm benefit. The gel may cause skin irritation or other side effects, and it is not yet proven to work better than a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

50 people

The number who actually took part.

Started

Dec 2019

Finished

Apr 2021

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The subject must have had at least 10 (with at least 3 on the face) clinically typical BCCs present within 24 months prior to Screening and Randomization (Baseline/Day 1). Additionally, the subject must have at least 2 BCCs with longest diameter \<5 mm present on the face prior to Screening and Randomization (Baseline/Day 1). 2. The subject must be willing to abstain from application of a non-study topical medication (prescription or over the counter) to facial skin for the duration of the trial except as prescribed by the Investigator. Exclusion Criteria: 1. The subject has been previously diagnosed with Gorlin syndrome 2. On medical history, family history or clinical examination there is a suspicion that the patient has Gorlin syndrome. 3. Patients with a family history of medulloblastoma 4. The subject has used topical treatment to the face or systemic therapies that might interfere with the evaluation of the study IP. 5. The subject has uncontrolled systemic disease. 6. The subject has been treated for invasive cancer within the past 5 years excluding non-melanoma skin cancer, Stage I cervical cancer, ductal carcinoma in situ of the breast, or chronic lymphocytic leukemia (CLL) Stage 0.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-Gorlin high-frequency basal cell carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basal cell carcinoma nevoid basal cell carcinoma syndrome Rombo syndrome skin basal cell carcinoma syndromic disease xeroderma pigmentosum

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent basal cell carcinoma

Contacts and locations

Locations

  • Axiom Research, LLC

    Apple Valley, California, 92307, United States

  • Axiom Research, LLC

    Colton, California, 92324, United States

  • Center for Dermatology Clinical Research, Inc.

    Fremont, California, 94538, United States

  • Dermatology Research Associates

    Los Angeles, California, 90045, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Grekin Skin Institute

    Warren, Michigan, 48088, United States

  • Leavitt Medical Associates of Florida

    Ormond Beach, Florida, 32174, United States

  • Palm Beach Dermatology Research

    Delray Beach, Florida, 33484, United States

  • PellePharm Investigative Site

    Saint Augustine, Florida, 32080, United States

  • PellePharm Investigative Site

    Henderson, Nevada, 89052, United States

  • Skin Laser and Surgery Specialists of NY&NJ

    Hackensack, New Jersey, 07601, United States

  • The Dermatology Center of Newport

    Newport Beach, California, 92660, United States

  • The Indiana Clinical Trials Center

    Plainfield, Indiana, 46168, United States

  • University of Utah

    Murray, Utah, 84107, United States